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Background: Existing inconclusive data on the relationship between vitamin D status and human glucose
homeostasis suggests that other factors, such as adiposity, might influence this relationship. The present study
aimed to investigate the association between 25-hydroxyvitamin D [25(OH)D] and fasting plasma glucose (FPG) in
the context of different amounts of total body fat in a healthy community-based population in Bangkok, Thailand.
Methods: This cross-sectional study was a part of health survey of employees of the Electricity Generating Authority
of Thailand. There were 1,990 healthy subjects (72.8% male) in this study. Total body fat was measured by
bioelectrical impedance analysis. Total serum 25(OH)D, 25(OH)D3 and 25(OH)D2 were measured by LC-MS/MS.
Results: Age (r = 0.134, p < 0.001) and FPG (r = 0.089, p < 0.001) were positively correlated with 25(OH)D levels, while
total body fat mass (r = −0.049, p = 0.03) were negatively correlated with 25(OH)D levels. 25(OH)D levels were higher
in males than in females (65.0 ± 0.5 vs. 53.5 ± 0.5 nmol/L, p < 0.001). After controlling for age, gender and total fat
mass, FPG was no longer correlated with 25(OH)D. However, when subjects were stratified according to fat-free
mass tertiles and controlled for age and gender, there was a positive, although weak association between 25(OH)D
levels and FPG (p = 0.01) in the lowest tertile.
Conclusions: We therefore speculate that adiposity might influence the relationship of vitamin D status and FPG.
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In addition to its established role in calcium and bone me-
tabolism, vitamin D possesses numerous other biological
functions [1,2]. With regard to glucose homeostasis, it has
been shown that vitamin D affects pancreatic beta-cell
proliferation and survival [3,4]. It has also been demon-
strated that vitamin D improves insulin sensitivity [5,6].
At the population level, several association studies have
demonstrated a relationship between impaired vitamin D
status and higher risk of prevalence as well as incidence of
diabetes [7-9], although these findings are not undisputed.
We found in a recent study of subjects from the 4th Thai
National Health Examination Survey (2,641 adults, aged
15–98) that low 25(OH)D3 but not 25(OH)D2 level was* Correspondence: hataikarnn@hotmail.com
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distribution, and reproduction in any mediumsignificantly associated with increased odds of diabetes
only in the subgroup of urban elderly (≥70 years old) [10].
It is thus likely that if vitamin D does indeed affect glucose
homeostasis, its influence is probably minute and there
may be other interacting factors, for example body mass
index (BMI), which cause results from population studies
to be less consistent. Studies in vitamin D receptor (VDR)
knockout mice revealed a lean phenotype resistant to diet-
induced obesity [11,12], suggesting that vitamin D may
have a role in promoting adipose tissue development in an
in vivo context. Because low vitamin D status is associated
with human obesity [13-15], it is possible that vitamin D
action in adipose tissue underlies the relationship between
vitamin D and glucose homeostasis in humans. The aim
of this study is to explore the relationship between
25(OH)D, a marker of vitamin D status, and fasting
plasma glucose (FPG) in the context of different amountsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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in Bangkok, Thailand. The secondary objective is to inves-
tigate the association between 25(OH)D and FPG in sub-
groups of subjects stratified by gender and age.
Methods
This study was part of a health survey of 1,990 employees
of the Electricity Generating Authority of Thailand (EGAT).
Institutional Review Board approval was obtained prior to
the commencement of the study, and all subjects gave
informed consent. Described in detail elsewhere [16], sur-
vey data was collected by using self-administered ques-
tionnaires, physical examinations, electrocardiography,
chest radiography, and blood analysis. Anthropometric
variables including weight, height and waist circumfer-
ences were measured using standard techniques in all
subjects [17]. Waist circumference was measured at the
midway between the last rib and the iliac crest [17].
BMI was derived by weight (kg)/height(m)2. Body com-
position was determined after at least 3 h of fasting
using multifrequency bioelectrical impedance analysis
with eight-point tactile electrodes (InBody 720; Biospace,
Seoul, Korea). Fasting blood samples were obtained and
sent for laboratory analysis of fasting plasma glucose
(FPG) and 25(OH)D measurements. The study was ap-
proved by the IRB of Ramathibodi hospital, Mahidol
University.
Serum 25-hydroxyvitamin D [25(OH)D] measurement
Serum 25(OH)D2 and 25(OH)D3 were analyzed by LC-MS/
MS with an Agilent 1200 Infinity liquid chromatograph
(Agilent Technologies, Waldbronn, Germany) coupled to a
QTRAP® 5500 tandem mass spectrometer (AB SCIEX,
Framingham MA, USA) using a MassChrom® 25-OH-
Vitamin D3/D2 diagnostics kit (ChromSystems, Munich,
Germany). The summation of serum 25(OH)D2 and 25
(OH)D3 [total 25(OH)D] was used to reflect vitamin DTable 1 Clinical characteristics of the study population
Parameters Male n = 1,44
Age (years) 40.1 ± 0.2 (25–5
BMI (kg/m2) 24.5 ± 0.1 (15–4
Waist circumference (WC) (cm) 88.8 ± 0.2 (54–14
Fasting plasma glucose (FPG) (mmol/L) 5.2 ± 0.0 (4–17.
Muscle mass (kg) 29.4 ± 0.1 (18.4–4
Total body fat mass (kg) 17.6 ± 0.2 (2.9–68
Percent body fat (%) 24.5 ± 0.2 (6.7–46
Vitamin D status
<50 nmol/L (n = 433) 44 ± 0.5 (n = 20
≥50 nmol/L (n = 1,592) 68.5 ± 0.5 (n = 1,2
Data is expressed as mean ± SEM (range).
Body composition was assessed by bioelectrical impedance analysis (BIA).status. Vitamin D deficiency was defined as having
25(OH)D levels of less than 50 nmol/L [18]. The inter-
assay and intra-assay coefficients of variation of total
serum 25(OH)D level were 6.3% and 5.0%, respectively.
Statistical analysis
Data were expressed as mean ± standard error of the mean
(SEM). All data were normally distributed. Differences be-
tween two groups were assessed by Student’s t-test. The
correlations between dependent and independent vari-
ables were tested with Pearson correlation. Multiple linear
regression analysis was performed to identify the associ-
ation between FPG (the dependent variable) and 25(OH)
D in each subgroup, stratified by gender (male vs. female),
age (25–34, 35–44 and 45–54 years) and tertile of total
body fat. A p value less than 0.05 was considered statisti-
cally significant. All analyses were performed using the
SPSS statistical software package, version 17.0 (SPSS Inc.,
Chicago IL, USA).
Results
Table 1 demonstrates the clinical characteristics of the
study population. Subjects were mostly males (n = 1,449,
72.8%) because of the demographic structure of EGAT.
A data comparison between males and females revealed
that males were slightly older, had significantly higher
BMI, waist circumference (WC), fasting plasma glucose
(FPG) and muscle mass, and significantly lower total
body fat mass.
With regard to vitamin D status, mean total 25(OH)D
concentrations were significantly higher in males than in
females (65.0 ± 0.5 vs. 53.5 ± 0.5 nmol/L, P < 0.001). The
dominant form of total 25(OH)D in this population
group was 25(OH)D3. As expected, females had a higher
prevalence of vitamin D deficiency: 43.1% of females had
25(OH)D less than 50 nmol/L, whereas 13.9% of males
were classified as vitamin D deficient (Table 1). Only 3 of9 Female n = 541 P value
4) 39.5 ± 0.3 (25–54) 0.05
8) 22.0 ± 0.2 (15–39) <0.001
9) 78.0 ± 0.4 (57–112) <0.001
8) 4.9 ± 0.0 (3.7–17.2) <0.001
4.4) 19.7 ± 0.1 (13.4–29.0) <0.001
.1) 18.3 ± 0.3 (6.8–46.4) 0.04
.7) 32.5 ± 0.3 (16.9–51.1) <0.001
1) 42 ± 0.5 (n = 233) 0.001
48) 62.2 ± 0.5 (n = 308) <0.001
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Figure 1 Scatter plots of fasting plasma glucose and total 25(OH)D
according to body fat mass tertiles.
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than 25 nmol/L.
Univariate analyses revealed that age (r = 0.134, p <
0.001), FPG (r = 0.089, p < 0.001) and total body fat
mass (r = −0.049, p = 0.027) were significantly, although
weakly correlated with 25(OH)D levels. When classified
subjects into 3 groups according to fat mass tertiles, a
positive association between 25(OH)D and FPG was con-
sistently found across 3 groups, but reached statistically
significance only in the lowest tertile group (Figure 1).
Multiple linear regression analysis showed that age, gen-
der and total body fat mass, but not 25(OH)D, were inde-
pendently correlated with FPG. However, when subjects
were stratified according to fat mass tertiles and that the
analysis was controlled for age and gender, it was found
that there was a significant association (p = 0.01), although
a weak positive correlation (r = 0.097), between 25(OH)D
levels and FPG only in the lowest tertile group, as
shown in Table 2. Nevertheless, no relationship between
25(OH)D and FPG was detected when subjects were
stratified according to age group (controlled for gender
and body fat mass) or gender (controlled for age and
body fat mass) (Table 2).
Discussion
There is increasing evidence that vitamin D status may
modify the risk of type 2 diabetes. Most of the studies
looking into the relationship between 25(OH)D levels or
vitamin D supplementation and FPG, glucose homeostasis
or incidence of new onset of type 2 diabetes have been
performed in Caucasian populations [7-9]. The difference
of this relationship between Caucasians and Asians has
not been well recognized. In the present study, no associ-
ation was demonstrated between vitamin D status and
FPG. The same finding was reported in a study of 380
Malay adults (mean age of 48.5 years; 42% male). Investi-
gators classified subjects into two groups, vitamin D
insufficient [25(OH)D levels <50 nmol/L] and vitamin D
sufficient [25(OH)D levels ≥50 nmol/L], and found no
correlation between 25(OH)D levels and FPG [19]. On the
other hand, in the Fourth Korea National Health and Nu-
trition Examination Survey (n = 5,787; mean age of 48.5
(male) and 49.1 (female) years; 42% male), 25(OH)D levels
were inversely associated with FPG after adjusting for age
and sex [20]. This was in accordance with the findings in
a study of 3,262 elderly Chinese (age 50–70 years; 44%
male), where 25(OH)D levels were negatively associated
with FPG after controlling for age, sex and BMI [21].
Differences in study results can be partly explained by dif-
ferent subject characteristics, i.e. the subjects in our study
were relatively young and predominantly male.
In this study, we also confirmed a negative correlation
between 25(OH)D and degree of adiposity as defined by
BMI, WC (data not shown) and total body mass. Thepredominant source of vitamin D in these subjects was
from sun exposure. It has been reported that with a simi-
lar amount of 7-dehydrocholesterol in the epidermis and
using a similar amount of UVB irradiation, serum vitamin
D3 levels of obese subjects were 50% lower than those of
non-obese subjects; this suggested the possibility of se-
questration of vitamin D in expanded adipose tissue [22].
In a hypocaloric intervention study, with 10% weight loss
Table 2 Adjusted association of serum FPG and 25(OH)D








Male (n = 1,449) 65 ± 0.5 0.031 0.25
Female (n = 541) 53.5 ± 0.5 0.042 0.35
Age2
[n, range of age (years)]
group 1 (n = 402, age
25–34)
58.5 ± 0.8 0.023 0.64
group 2 (n = 1,064, age
35–44)
62.5 ± 0.5 0.044 0.13
group 3 (n = 524, age
44–54)
63.8 ± 0.8 0.039 0.36
Total body fat mass3
[mean ± SEM; range (kg)]
1st tertile (n = 674)
(11.5 ± 0.1; 2.9–14.5)
62.5 ± 0.8 0.097 0.01
2nd tertile (n = 664)
(17.0 ± 0.1; 14.6–19.5)
62.3 ± 0.5 −0.013 0.73
3rd tertile (n = 652)
(25.1 ± 0.2; 19.6–68.1)
61 ± 0.5 0.025 0.51
Data is expressed as mean ± SEM.
1controlled for age and body fat mass; 2controlled for gender and body fat
mass; 3controlled for age and gender.
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vitamin D intake [23]. It is also conceivable that reducing
fat mass may somehow influence the metabolism of vita-
min D and some of its effects.
In contrast to the results of a previous study in Thailand
[10], which demonstrated an association between lower
vitamin D status and an increased risk of diabetes in
subgroup of older subjects residing in urban areas, the
present study reported the reversed direction of the rela-
tionship in the younger age group. A statistical interaction
was also demonstrated between body fat mass, vitamin D
status and FPG. In the lowest tertile of body fat mass
subgroups, the higher the participants’ 25(OH)D levels,
the higher their FPG; this was in contrast to previous
studies in both Caucasians and Asians [20,21], where the
results showed an opposite trend. Although the strength
of the statistical association was relatively weak and the
underlying basis unclear, the finding is intriguing. In spite
of the fact that most epidemiologic studies demonstrated
lower circulating vitamin D is generally associated with in-
creased adiposity [24], underlined mechanism of the asso-
ciation has not been well established. Nevertheless, the
mechanistic studies of this correlation in mouse model are
complex. For example VDR knockout mice were lean [11].
The same study also demonstrated an increase in uncoup-
ling protein (UCP), a marker of brown adipose tissue [11].The main function of brown adipose tissue is to regulate
thermogenesis by expressing UCPs that separate oxidative
phosphorylation from ATP (adenosine triphosphate)
production, producing heat in place of ATP [25]. Con-
firmatory data from a recent study of overexpression of
VDR in mice demonstrated an increase in fat mass,
mainly due to markedly reduced energy expenditure. In
addition, the expression of genes involved in the regula-
tion of fatty acid transport, thermogenesis and lipolysis
were suppressed in the transgenic mice [25]. Taken to-
gether, these data confirm an important role of VDR in
the regulation of energy metabolism. Brown adipose
tissue has recently been confirmed to be functionally ac-
tive in human adults [26], and is likely to decrease with
age [26]. It is therefore conceivable that in younger
adults, who may possess a higher amount of brown adi-
pose tissue, vitamin D may have a greater influence in
inhibiting the function of brown adipose tissue rather
than in inhibiting lipogenesis and its metabolic conse-
quences in white adipose tissue. Further studies to ex-
plore the comparative effects of vitamin D on brown
and white adipose tissues are warranted.
If vitamin D does indeed increase FPG, it remains
unclear whether it would increase diabetes risk and dia-
betic complications. Although FPG is generally used for
the diagnosis of diabetes [27], it has been recognized
that its relationship to diabetic complications may not
be straightforward. For example, MODY (maturity onset
diabetes of the young) patients with mutation in the glu-
cokinase gene presented with elevated FPG but generally
without a significant increase in average HbA1c and
diabetes-related complications [28]. Further studies to
clarify the issue, using measures more directly related to
diabetes complications, are therefore warranted. One of
the limitation of this study is we could only assess FPG
(single measurement) and did not examine other meta-
bolic measurement such as HbA1c, fasting insulin, lipid
profile. We did not have data about previous history of
diabetes or metabolic syndrome in our study subjects.
Nonetheless, statistical analysis which including or ex-
cluding subjects who had FPG ≥ 7 mmol/L (126 mg/dL)
provided the same results. In addition, other measures
that can potentially affect both diabetic risk and vitamin
D such as calcium were not evaluated.
Conclusion
In conclusion our findings were contrary to those of most
studies, where a relationship between vitamin D status
and diabetes has been demonstrated. Although the present
findings need to be replicated in separate populations, they
suggest the heterogeneity of the effect of vitamin D status
based on interacting factors such as body fat mass; this
may underlie the inconsistent results among previously
performed studies.
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